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Abstract
Introduction: The results of large clinical studies indicate that angiotensin-converting enzyme (ACE) inhibitors are effective agents in
patients with coronary artery disease (CAD), even if their blood pressure is within normal limits.
Material and methods: In the present study, we compared the effect of plasma- and tissue-type angiotensin-converting enzyme inhibitors
on plasma levels of leptin and adiponectin in normotensive subjects with isolated CAD. We analyzed the samples obtained from 45 patients
with isolated CAD, treated for 90 days with enalapril (20 mg/d, n = 15) or perindopril (4 mg/d, n = 16), or not receiving angiotensin-converting
enzyme inhibitors (n = 14). Plasma leptin and adiponectin levels were determined at baseline, and after 30 and 90 days of treatment.
Results: Compared to healthy subjects (n = 15), CAD patients had lower plasma levels of adiponectin and higher plasma content of leptin.
Neither enalapril nor perindopril treatment was associated with any significant changes in blood pressure. Administration of perindopril
resulted in an increase in plasma adiponectin and a reduction in plasma leptin. No significant changes in these hormones were observed
after enalapril treatment.
Conclusions: Our results indicate that perindopril is superior to enalapril when it comes to affecting the hormonal function of human
adipose tissue. This suggests that tissue-type angiotensin-converting enzyme inhibitors are a better treatment option for normotensive
individuals with CAD than plasma-type ones. (Pol J Endocrinol 2010; 61 (3): 280–286)
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Streszczenie
Wstęp: Wyniki dużych badań klinicznych wskazują, że inhibitory konwertazy angiotensyny (ACE, angiotensin-converting enzyme) są sku-
teczne w leczeniu pacjentów z chorobą niedokrwienną serca (CAD, coronary artery disease), nawet wówczas, gdy ciśnienie tętnicze jest
w granicach normy.
Materiał i metody: W niniejszym badaniu porównano wpływ tkankowego i osoczowego inhibitora ACE na stężenie w osoczu leptyny
i adiponektyny u chorych z chorobą wieńcową i prawidłowym ciśnieniem tętniczym krwi. W badaniu analizowano próbki uzyskane od
45 pacjentów, którym przez 90 dni podawano enalapril (20 mg/d., n = 15), perindopril (4 mg/d., n = 16) lub u których nie stosowano
żadnego inhibitora ACE (n = 14).
Wyniki: Stężenie leptyny i adiponektyny w osoczu oceniano w warunkach wyjściowych i po 30 oraz 90 dniach terapii. Wyjściowe stęże-
nie adiponektyny było niższe, zaś leptyny wyższe niż w grupie zdrowych ochotników (n = 15). Oba oceniane leki nie wpływały znamien-
nie na wartość ciśnienia tętniczego. Perindopril powodował wzrost adiponektynemii i spadek leptynemii. Natomiast enalapril nie powo-
dował statystycznie znamiennych zmian stężeń obu tych adipokin.
Wnioski: Uzyskane wyniki dowodzą przewagi perindoprilu nad enalaprilem w zakresie wpływu na funkcję hormonalną tkanki tłuszczo-
wej. Wskazuje to na preferencję tkankowych nad osoczowymi inhibitorami ACE w grupie osób z chorobą wieńcową i prawidłowym
ciśnieniem tętniczym. (Endokrynol Pol 2010; 61 (3): 280–286)
Słowa kluczowe: inhibitory konwertazy angiotensyny, choroba wieńcowa, ciśnienie tętnicze, leptyna, adiponektyna
Introduction
Angiotensin-converting enzyme (ACE) inhibitors are
able to reduce cardiovascular and cerebrovascular mor-
tality and morbidity not only in subjects with arterial
hypertension or heart failure [1]. Perindopril [2] and
ramipril [3] were evidenced to decrease the frequency
of cardiovascular and cerebrovascular events, fatal and
non-fatal, in individuals with atherosclerosis free from
systolic dysfunction of the left ventricle or heart failure
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[2, 4]. The finding that the clinical benefits of ACE in-
hibitors were much more strongly expressed compared
with only a small reduction in blood pressure suggests
that these benefits go beyond their hypotensive action
[2, 4]. They may be explained by numerous pleiotropic
actions being exhibited by ACE inhibitors, such as anti-
inflammatory and antioxidant effects, endothelium-pro-
tective actions, antithrombotic, profibrinolytic, and anti-
aggregatory effects, and regulation of muscle cell
growth and migration [5–8].
An interesting target for ACE inhibitors is the hor-
monal function of human adipose tissue. Although var-
ious studies have determined the action of these agents
on adipokine plasma levels, their results are inconsis-
tent. Plasma leptin levels decreased after administra-
tion of ramipril to hypertensive subjects [9], after ad-
ministration of enalapril to patients with concomitant
hypertension and obesity [10], after treatment of Spra-
gue-Dawley rats with perindopril [11], after adminis-
tration of perindopril to rats with genetically-induced
increased angiotensin II activity [12], and after treatment
of normotensive adult Wistar rats with enarenal [13].
Plasma levels of adiponectin increased in hypertensive
individuals treated with cilazapril [14] or ramipril [9],
type 2 diabetes patients treated with ramipril [15], pa-
tients with both arterial hypertension and metabolic
syndrome receiving ramipril [16], in enalapril-treated
healthy male subjects exposed to a high-sodium diet
[17], and in enalapril-treated spontaneously hyperten-
sive rats [18]. However, other authors observed no
changes in leptinaemia after administration of ACE in-
hibitors in hypertensive obese subjects [19] and in pa-
tients with essential hypertension [20]. Similarly, adi-
ponectinaemia remained unaltered in enalapril-treat-
ed patients with essential hypertension [21] and in rami-
pril-treated type 2 diabetic subjects [22].
These inter-study differences in ACE inhibitor ac-
tion on plasma adipokines may result from various in-
clusion criteria and/or different drugs used in particu-
lar studies. Unfortunately, as stated above, the studies
determining ACE inhibitor action on adipose tissue
products were conducted only on animals or included
individuals with arterial hypertension, diabetes melli-
tus, and obesity. Therefore, it remains unknown wheth-
er similar effects are also observed in individuals with
isolated coronary artery disease (CAD). Recently we
have shown that perindopril was superior to enalapril
in exhibiting anti-oxidant, anti-thrombotic, and profi-
brinolytic effects in CAD patients, and these actions may
contribute to the clinical effectiveness of tissue ACE in-
hibitors in the primary and secondary prevention of
cardiovascular disorders [23]. Therefore, in the present
study we compared the effect on perindopril and enal-
april on plasma adipokine levels in patients suffering
from CAD free from arterial hypertension, diabetes, obe-
sity, or any form of dyslipidaemia. Both adiponectin and
leptin were chosen as they belong to the best known
adipose tissue products [24, 25] and their plasma levels
determine the risk of CAD and its complications [26–29].
Material and methods
We retrospectively analyzed plasma samples obtained
from 45 CAD patients participating in our previous
study [23]. Patients (aged 42–65 years) were eligible for
the study if they had stable CAD with the presence of
clinical symptoms of this disorder despite treatment
with acetylsalicylic acid, a b-blocker, and a statin. CAD
was diagnosed on the basis of clinical symptoms and/or
a positive result of an exercise test performed using
a bicycle ergometer (horizontal or down-sloping ST-seg-
ment depression of at least 1 mm at 80 ms after the
J point). In the original study [23], patients were exclud-
ed if they met at least one of the following criteria:
1) any form of acute coronary syndrome or a previous
history of acute coronary syndromes; 2) chronic coro-
nary artery disease being an indication for coronarog-
raphy; 3) other acute ischaemic conditions (presently
or in the past); 4) diabetes mellitus; 5) obesity (BMI
> 30 kg/m2); (6) symptomatic congestive heart failure;
7) any form of arterial hypertension; 8) any acute and
chronic inflammatory process; 9) impaired renal or he-
patic function; 10) malabsorption syndromes; 11) pre-
vious treatment with ACE inhibitors or the existence of
contraindications to administration of ACE inhibitors;
and 12) poor patient compliance. In the present study,
we also discarded samples obtained from individuals
with any form of dyslipidaemia (defined as plasma total
cholesterol more than 200 mg/dL, LDL-cholesterol above
130 mg/dL and triglycerides less than 150 mg/dL).
Study design
The original study included 90 patients who, after pro-
viding written informed consent and approval the study
protocol by the local bioethical committee, were allo-
cated into one of three treatment groups. After discard-
ing samples obtained from dyslipidaemic individuals,
we analyzed samples obtained from 15 enalapril-treat-
ed subjects (20 mg daily), samples coming from 16 per-
indopril-treated individuals (4 mg daily), and samples
from 14 subjects receiving no ACE inhibitor. The con-
trol group comprised samples obtained from 15 healthy
individuals. The ACE inhibitor treatment lasted 90 days
with no changes in the therapy made throughout the
study. The samples had been collected before and after
30 and 90 days of therapy. During the treatment, sys-
tolic and diastolic blood pressure were monitored at
each visit in a sitting position using standard cuff equip-
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ment. They were determined during Korotkoff sounds
1 and 5. The values used in statistical analyses were the
means of 3 measurements taken at intervals of at least
5 min, starting 15 min after the patient had sat down.
Laboratory assays
The plasma samples, stored at –70°C, were thawed at room
temperature just before analysis. To minimize analytical
errors, all measurements were performed in duplicate.
Plasma glucose content was measured using a glucose
oxidase method (Beckman, Palo Alto, USA). Plasma lipids
(total cholesterol, LDL-cholesterol, HDL-cholesterol, and
triglycerides) were determined by a colorimetric method
using bioMerieux reagents (Marcy-l’Etoile, France).
Leptin and adiponectin levels were estimated using
commercially available ELISA kits obtained from R&D
Systems (McKinley Place N.E. Minneapolis, USA) ac-
cording to the manufacturer’s instructions. Intra- and
interassay coefficients of variation of all measurements
were as described previously [30].
Statistical analysis
Results are presented as means ± SD. Comparisons be-
tween the groups were performed using one-way ANO-
VA followed by post hoc Bonferroni test (arterial pressure,
lipid profile, and plasma glucose) or using the Kruskall-
Wallis test followed by the Mann-Whitney U test (leptin
and adiponectin). Pre-, inter-, and post-treatment results
within the same treatment group were compared with
either Student’s paired t test (arterial pressure, lipid pro-
file, and plasma glucose) or the Wilcoxon test (leptin and
adiponectin). For categorical variables, the c2 test was used.
Correlations were assessed using Kendall’s tau test. Val-
ues of p < 0.05 were considered statistically significant.
Statistical analysis was carried out using GraphPad Prism
2.01 software for Windows (GPA-26576-117).
Results
Baseline characteristics (Table I)
The groups treated with perindopril, those treated with
enalapril, and those not receiving ACE inhibitors were com-
parable in terms of sex, weight, age, medical background,
clinical characteristics, and other demographic data. Most
CAD patients were treated with statins, b-adrenolytics, and
acetylsalicylic acid, with no differences between the treat-
ment groups. Patients with CAD exhibited higher plasma
leptin levels and lower plasma adiponectin content.
Effect of ACE inhibitors on blood pressure
Both perindopril and enalapril only tended to reduce
blood pressure by 2.2/1.3 and 2.8/1.5 mm Hg (perin-
Table I. Baseline characteristics of patients
Tabela I. Wyjściowa charakterystyka pacjentów
Healthy Patients not treated Enalapril-treated Perindopril-treated
subjects with ACE inhibitor  group group
Number of patients 15 14 15 16
Age (years) 50.3 ± 6.5 53.2 ± 8.9 51.2 ± 6.2 48.2 ± 6.0
Females (%) 33.3 28.6 33.3 31.3
BMI [kg/m2] 26.0 ± 3.1 26.8 ± 2.4 27.1 ± 2.3 26.4 ± 2.6
Smokers (%) 20.0 21.4 20.0 25.0
Systolic blood pressure [mm Hg] 120.1 ± 5.5 123.9 ± 6.4 124.3 ± 8.3 125.1 ± 7.4
Diastolic blood pressure [mm Hg] 77.2 ± 6.2 78.1 ± 7.1 78.8 ± 7.8 80.4 ± 6.4
Medications
Statins (%) 0 85.7*** 86.7*** 93.8***
Acetylsalicylic acid (%) 0 85.7*** 86.7*** 87.5***
b-adrenolytics (%) 0 92.9*** 93.3*** 81.3***
Total cholesterol [mg/dL] 168.2 ± 10.6 171.3 ± 14.3 173.2 ± 11.2 169.4 ± 12.1
LDL-cholesterol [mg/dL] 91.3 ± 5.9 95.2 ± 5.7 98.5 ± 6.2 94.2 ± 8.6
HDL-cholesterol [mg/dL] 51.8 ± 3.5 49.5 ± 3.2 50.1 ± 3.5 51.0 ± 4.0
Triglycerides [mg/dL] 118.3 ± 14.3 120.2 ± 15.1 125.2 ± 7.8 116.0 ± 12.8
Glycaemia [mg/dL] 88.3 ± 4.2 90.5 ± 5.7 89.1 ± 6.4 88.7 ± 7.8
Leptin [ng/mL] 8.5 ± 1.1 12.9 ± 1.3*** 13.2 ± 1.5*** 12.8 ± 1.6***
Adiponectin [mg/L] 8.9 ± 1.1 5.6 ± 0.8*** 5.3 ± 1.3*** 5.2 ± 1.4***
Each value represents the mean ± SD; ***p < 0.001 v. healthy subjects
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dopril) and by 3.5/2.0 and 3.0/1.7 mm Hg (enalapril) af-
ter 30 and 90 days of treatment, respectively. No changes
in blood pressure were observed in the remaining
groups of patients (data not shown).
Effect of ACE inhibitors
on plasma adipokine levels
Leptin (Fig. 1)
Administered for 30 days, perindopril tended to reduce
plasma leptin levels (by 18.8%, p = 0.075). After 90 days,
perindopril decreased plasma levels of this protein by
25.0% (p  <  0.01). At the end of the study, plasma levels
of leptin in CAD patients did not differ from those ob-
served in healthy subjects.
Thirty-day management with enalapril did not af-
fect plasma leptin, while at the end of the treatment
period the drug induced an insignificant decrease of
leptinaemia (by 16.7%, p = 0.082). After 90 days of enal-
april administration, plasma leptin levels still exceeded
those observed in the control group.
In normotensive individuals with CAD who were
not treated with ACE inhibitors, plasma leptin levels
remained unaltered throughout the study.
Adiponectin (Fig. 2)
Perindopril increased plasma adiponectin levels by
23.1% (p < 0.05) and by 61.5% (p < 0.001) after 30 and
90 days of treatment, respectively. A perindopril-in-
duced increase in adiponectinaemia was stronger after
90 days than after 30 days of treatment (p < 0.01). At
the end of the study, plasma adiponectin content in
CAD patients did not differ from those observed in
healthy subjects.
Enalapril only insignificantly increased adiponectin
levels. After 30 days this reduction was 18.9%
(p = 0.069), while at the end of the study it was 20.8%
(p = 0.056). At the end of the study, plasma adiponec-
tin levels were still higher than in the control group.
No changes in plasma adiponectin content were
observed in CAD patients who were not given any ACE
inhibitor.
Comparisons between the groups (Fig. 1 and 2)
Perindopril was superior to enalapril in reducing plas-
ma leptin levels (p < 0.01) and increasing plasma adi-
ponectin (p < 0.001).
Correlations
At entry, plasma content of leptin correlated weakly
with both systolic (r = 0.32, p < 0.05) and diastolic (r =
= 0.35, p < 0.01) blood pressure. There was an inverse
correlation between plasma adiponectin and systolic
(r = –0.38, p < 0.01) and diastolic (r = –0.31, p < 0.05)
blood pressure. No correlation was observed between per-
indopril and enalapril action on plasma adipokine levels
and the effects of these agents on systolic and diastolic
arterial pressure, plasma glucose, and lipid profile.
Figure 1. Effect of angiotensin-converting enzyme inhibitors on plasma leptin levels in normotensive patients with coronary artery
disease. Data represent the mean ± SD; **p < 0.01, ***p < 0.001 v. healthy subjects; ##p < 0.01 v. pretreatment values; ^^p < 0.01
the effect of perindopril stronger than that of enalapril at the end of the study
Rycina 1. Wpływ inhibitorów enzymu konwertazy angiotensyny na stężenie leptyny w osoczu pacjentów z chorobą niedokrwienną
serca i prawidłową wartością ciśnienia tętniczego. Wyniki przedstawiają średnią ± odchylenie standardowe; **p < 0,01, ***p < 0,001
v. zdrowi ochotnicy; ##p < 0,01 v. wartość przed leczeniem; ^^p < 0,01 pod koniec terapii wpływ perindoprilu silniejszy od enalaprilu
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The major finding of our study is that perindopril ad-
ministered to normotensive CAD patients exhibited
a stronger pleiotropic effect on the hormonal function
of adipose tissue than enalapril, and that the drug-in-
duced changes in plasma adipokines were not related
to hypotensive or metabolic effects of ACE inhibitors.
We observed that CAD patients exhibited higher
plasma levels of leptin as well as reduced plasma con-
tent of adiponectin, when compared with healthy con-
trols. These results cannot be interpreted as a result of
the presence of concomitant disorders known to affect
adipokine production, as all subjects suffering from di-
abetes, obesity, arterial hypertension, and dyslipidaemia
were excluded from the study. Therefore, differences
between CAD individuals and healthy subjects seem to
reflect the presence of atherosclerotic changes in the
coronary vasculature. Taking into account that most
included patients were treated with cardiovascular
drugs, we cannot exclude that the difference may be
even more pronounced in subjects with either untreat-
ed or insufficiently treated CAD. Interestingly, at base-
line conditions plasma levels of leptin and adiponectin
correlated with both systolic and diastolic blood pres-
sure. This means that in subjects with concomitant pres-
ence of CAD and arterial hypertension, abnormalities
in adipokine release are probably more expressed than
in individuals with only one of these disorders.
Both perindopril and enalapril treatment were well
tolerated and resulted in only an insignificant reduc-
tion of both diastolic and systolic blood pressure. This
indicates that, if administered at doses used in our study,
ACE inhibitors do not increase the risk of excessive re-
duction in blood pressure and therefore may be safely
used in CAD subjects without arterial hypertension.
To the best of our knowledge our study is the first
one which assessed adipokine levels during treatment
with more than one ACE inhibitor. This fact seems
a little surprising taking into account the marked phar-
macokinetic and pharmacodynamic differences be-
tween various ACE inhibitors. Some of these agents
(perindopril, quinapril, and ramipril) exhibit a strong
affinity for target tissues, while the others (captopril and
enalapril) are characterized by relatively weak tissue
affinity [31, 32]. The former group is often named tis-
sue-type, while the latter is known as plasma-type ACE
inhibitors. Our results, which showed much stronger
action of perindopril than enalapril on plasma adipok-
ine levels, indicate that pharmacokinetic and pharma-
codynamic differences between various ACE inhibitors
may determine the strength with which these agents
affect adipokine release. This finding seems to be clini-
cally relevant because both these adipose tissue prod-
Figure 2. Effect of angiotensin-converting enzyme inhibitors on plasma adiponectin levels in normotensive patients with coronary
artery disease. Data represent the mean ± SD; **p < 0.01, ***p < 0.001 v. healthy subjects; #p < 0.05, ###p < 0.001 v. pretreatment
values; $$p < 0.01 the effect stronger than after 30 days of treatment; ^^^p < 0.001 the effect of perindopril stronger than that of
enalapril at the end of the study
Rycina 2. Wpływ inhibitorów enzymu konwertującego angiotensynę na stężenie adiponektyny w osoczu pacjentów z chorobą
niedokrwienną serca i prawidłową wartością ciśnienia tętniczego. Wyniki przedstawiają średnią ± odchylenie standardowe; **p < 0,01,
***p < 0,001 v. zdrowi ochotnicy; #p < 0,05, ###p < 0,001 v. wartość przed leczeniem; $$p < 0,01 wpływ leku silniejszy niż po
30 dniach leczenia; ^^^p < 0,001 pod koniec terapii wpływ perindoprilu silniejszy od enalaprilu
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ucts are directly involved in atherogenesis. Adiponec-
tin exhibits a multidirectional anti-atherogenic action
because it inhibits proliferation of smooth muscle cells,
reduces macrophage cholesterol accumulation, pre-
vents macrophage foam cell transformation, inhibits the
endothelial expression of adhesive molecules, reduces
proinflammatory cytokine release, and retards the de-
velopment and progression of atherosclerotic lesions in
atherosclerosis-prone mouse strains [24, 33]. The oppo-
site action is produced by leptin, which enhances an-
giogenesis, stimulates oxidative stress in endothelial
cells, increases vascular wall calcium content, and may
induce proliferation and migration of smooth muscle
cells [25, 34]. Taking into account the relationship be-
tween low adiponectinaemia and high leptinaemia and
the risk of CAD and its complications [26–29], the ob-
tained results indicate that tissue-type ACE inhibitors
probably bring more benefits to subjects with isolated
CAD than plasma-type ones. The observed differences
between perindopril and enalapril may, in part, explain
inter-study differences concerning ACE inhibitor action
on plasma adipokines. Only an insignificant reduction
in plasma leptin and a slight increase in plasma adi-
ponectin are line with weak potency of enalapril to al-
ter plasma levels of total or high molecular weight
(HMW) adiponectin and HMW/total adiponectin ratio
in CAD patents, observed recently by other authors [35].
Interestingly, perindopril-induced and, to a lesser
extent, enalapril-induced increase in plasma adiponec-
tin and a reduction in plasma leptin did not correlate
with the insignificant reduction in blood arterial pres-
sure. A similar hypotensive-independent effect of per-
indopril on leptinaemia was found recently in rats [36].
This indicates that the improvement in adipose tissue
secretory function occurs irrespective of blood pressure
and that it is present in individuals in whom ACE in-
hibitors produce no effect on arterial pressure. This find-
ing is in line with our previous results [23]. Taking into
account the inverse relationship between plasma adi-
ponectin and the risk of CAD and the positive correla-
tion between plasma leptin and the risk of CAD, our
results may justify the routine use of ACE inhibitors in
normotensive CAD patients.
Our study excluded not only subjects with arterial
hypertension, but also individuals suffering from dia-
betes mellitus, obesity, and dyslipidaemia. Therefore,
treatment-induced improvement in adipose tissue func-
tion cannot be explained by improvement in glucose
and lipid metabolism and body weight.
It should be stressed that most patients included in
this study had been, before the beginning of the treat-
ment period, treated with acetylsalicylic acid, a statin,
as well as with a b-adrenolytic agent. The fact that de-
spite this, perindopril improved the hormonal function
of human adipose tissue, evidences the rationale of the
use of this agent, and probably also other tissue-type
ACE inhibitors in CAD patients, in whom clinically the
disease is controlled by other drugs. The fact that per-
indopril-induced changes in plasma adipokines did not
correlate with its action on plasma glucose and lipid
profile indicates that this action does not result from
metabolic effects of perindopril and that non-obese,
normoglycaemic and normolipidaemic patients may
benefit from this form of therapy.
The value of the obtained results may be limited by
at least two reasons. Firstly, our study was a retrospec-
tive analysis of the stored samples. However, the origi-
nal study was prospective in nature and patients were
randomized to perindopril or enalapril. Secondly, the
diagnosis of CAD was established indirectly on the ba-
sis of clinical manifestations and/or the results of the
exercise test. Because no coronary angiography was
performed, we cannot exclude that among the partici-
pants there were individuals misdiagnosed with CAD.
Conclusions
Our study has shown increased leptin and a reduced
adiponectin plasma levels in normotensive CAD pa-
tients. Perindopril has been found to be more effective
than enalapril, when it comes to affecting the hormon-
al function of human adipose tissue. This suggests that
tissue-type ACE inhibitors appear to be a better treat-
ment option for normotensive individuals with CAD
than plasma-type ones.
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